SERMs and cardiovascular disease in women. How do these agents affect risk?

T. L. Bush, Roger S Blumenthal, R. Lobo, T. B. Clarkson

Research output: Contribution to journalArticle

Abstract

The beneficial effects of SERMs, specifically tamoxifen in the treatment and prevention of breast cancer and raloxifene in the prevention of osteoporosis, are well established. In addition, numerous groups of investigators have reported that these agents have a positive impact on cardiovascular health, possibly as a result of their cholesterol-lowering and anticoagulation actions. Although studies clearly showed that tamoxifen therapy improved the levels of some types of lipids, the changes did not appear to translate into a decreased risk of cardiovascular disease. However, the risk of thromboembolic events (as well as endometrial cancer) was increased with the use of tamoxifen, which is often prescribed for breast cancer prevention in healthy women. Similarly, raloxifene treatment had modest positive effects on cardiovascular risk factors but was associated with an increased risk of thromboembolism. When viewed as a whole, study results dictate that the benefits of SERM use for the prevention of cardiovascular disease be carefully weighed against the potential risks.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalPostgraduate Medicine
VolumeSpec No
StatePublished - Mar 2001
Externally publishedYes

Fingerprint

Selective Estrogen Receptor Modulators
Cardiovascular Diseases
Tamoxifen
Breast Neoplasms
Thromboembolism
Endometrial Neoplasms
Osteoporosis
Therapeutics
Cholesterol
Research Personnel
Lipids
Health
Raloxifene Hydrochloride

ASJC Scopus subject areas

  • Medicine(all)

Cite this

SERMs and cardiovascular disease in women. How do these agents affect risk? / Bush, T. L.; Blumenthal, Roger S; Lobo, R.; Clarkson, T. B.

In: Postgraduate Medicine, Vol. Spec No, 03.2001, p. 17-24.

Research output: Contribution to journalArticle

Bush, T. L. ; Blumenthal, Roger S ; Lobo, R. ; Clarkson, T. B. / SERMs and cardiovascular disease in women. How do these agents affect risk?. In: Postgraduate Medicine. 2001 ; Vol. Spec No. pp. 17-24.
@article{b7f00ef856f14aa6aa4c6a95e0ae5079,
title = "SERMs and cardiovascular disease in women. How do these agents affect risk?",
abstract = "The beneficial effects of SERMs, specifically tamoxifen in the treatment and prevention of breast cancer and raloxifene in the prevention of osteoporosis, are well established. In addition, numerous groups of investigators have reported that these agents have a positive impact on cardiovascular health, possibly as a result of their cholesterol-lowering and anticoagulation actions. Although studies clearly showed that tamoxifen therapy improved the levels of some types of lipids, the changes did not appear to translate into a decreased risk of cardiovascular disease. However, the risk of thromboembolic events (as well as endometrial cancer) was increased with the use of tamoxifen, which is often prescribed for breast cancer prevention in healthy women. Similarly, raloxifene treatment had modest positive effects on cardiovascular risk factors but was associated with an increased risk of thromboembolism. When viewed as a whole, study results dictate that the benefits of SERM use for the prevention of cardiovascular disease be carefully weighed against the potential risks.",
author = "Bush, {T. L.} and Blumenthal, {Roger S} and R. Lobo and Clarkson, {T. B.}",
year = "2001",
month = "3",
language = "English (US)",
volume = "Spec No",
pages = "17--24",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",

}

TY - JOUR

T1 - SERMs and cardiovascular disease in women. How do these agents affect risk?

AU - Bush, T. L.

AU - Blumenthal, Roger S

AU - Lobo, R.

AU - Clarkson, T. B.

PY - 2001/3

Y1 - 2001/3

N2 - The beneficial effects of SERMs, specifically tamoxifen in the treatment and prevention of breast cancer and raloxifene in the prevention of osteoporosis, are well established. In addition, numerous groups of investigators have reported that these agents have a positive impact on cardiovascular health, possibly as a result of their cholesterol-lowering and anticoagulation actions. Although studies clearly showed that tamoxifen therapy improved the levels of some types of lipids, the changes did not appear to translate into a decreased risk of cardiovascular disease. However, the risk of thromboembolic events (as well as endometrial cancer) was increased with the use of tamoxifen, which is often prescribed for breast cancer prevention in healthy women. Similarly, raloxifene treatment had modest positive effects on cardiovascular risk factors but was associated with an increased risk of thromboembolism. When viewed as a whole, study results dictate that the benefits of SERM use for the prevention of cardiovascular disease be carefully weighed against the potential risks.

AB - The beneficial effects of SERMs, specifically tamoxifen in the treatment and prevention of breast cancer and raloxifene in the prevention of osteoporosis, are well established. In addition, numerous groups of investigators have reported that these agents have a positive impact on cardiovascular health, possibly as a result of their cholesterol-lowering and anticoagulation actions. Although studies clearly showed that tamoxifen therapy improved the levels of some types of lipids, the changes did not appear to translate into a decreased risk of cardiovascular disease. However, the risk of thromboembolic events (as well as endometrial cancer) was increased with the use of tamoxifen, which is often prescribed for breast cancer prevention in healthy women. Similarly, raloxifene treatment had modest positive effects on cardiovascular risk factors but was associated with an increased risk of thromboembolism. When viewed as a whole, study results dictate that the benefits of SERM use for the prevention of cardiovascular disease be carefully weighed against the potential risks.

UR - http://www.scopus.com/inward/record.url?scp=0035291315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035291315&partnerID=8YFLogxK

M3 - Article

VL - Spec No

SP - 17

EP - 24

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

ER -